Anakinra showed no clear difference in number of participants experiencing an attacka compared with placebo (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Anakinra showed no clear difference in adverse drug reactions compared with placebo (moderate certainty).
Anakinra showed no clear difference in clinical improvement D28 compared with standard care/placebo (moderate certainty).
Anakinra may leads to lower time to WHO Clinical Progression Score of level 7 or above compared with standard care/placebo (low certainty).
Anakinra showed no clear difference in time to death compared with standard care/placebo (low certainty).
It is very uncertain whether anakinra changes clinical improvement D60 or above compared with standard care/placebo (very low certainty).
Anakinra showed no clear difference in WHO Clinical Progression Score of level 7 or above D28 compared with standard care/placebo (low certainty).
Anakinra may leads to lower WHO Clinical Progression Score of level 7 or above D60 or above compared with standard care/placebo (low certainty).
Anakinra showed no clear difference in all‐cause mortality D28 compared with standard care/placebo (low certainty).
It is very uncertain whether anakinra changes all‐cause mortality D60 or above compared with standard care/placebo (very low certainty).
Anakinra showed no clear difference in adverse events compared with standard care/placebo (moderate certainty).
Anakinra showed no clear difference in serious adverse events compared with standard care/placebo (low certainty).
Anakinra showed no clear difference in time to clinical improvement compared with standard care/placebo (low certainty).